🌍 This will be BMS’ first European SDP facility for biologics manufacturing, supporting existing medicines and pipeline assets.
🧪 The facility is currently in the design phase and is expected to be completed by 2026.
💪 The investment will expand manufacturing capacity and accelerate the development of biologic therapies.
🔬 The new facility will add new technologies and capabilities to BMS’ existing operations in Cruiserath.
Introduction:
Bristol Myers Squibb (BMS) has announced a $400 million investment in its Dublin 15 Cruiserath Campus to build a sterile drug product (SDP) facility. The facility will support the manufacturing and supply of existing medicines and serve as a launch excellence facility for pipeline assets. This investment marks BMS’ first European SDP facility for biologics manufacturing.
- The investment will fund the construction and design of a sterile drug product (SDP) facility in Dublin.
- The facility will support the manufacturing and supply of existing medicines and serve as a launch excellence facility for pipeline assets.
- BMS’ commercial and pipeline portfolio includes therapeutic areas such as oncology, immunology, and hematology.
- This investment will significantly expand manufacturing and laboratory capacity in Cruiserath, adding new technologies and capabilities for SDP manufacturing.
- The co-location of drug substance and drug product manufacturing alongside global testing capabilities will enhance the global supply of medicinal products.
Conclusion:
BMS’ $400 million investment in a sterile drug product facility in Dublin will enhance their manufacturing and supply capabilities for existing medicines and pipeline assets. The facility’s construction and design phase is expected to begin soon, with completion scheduled for 2026. This investment demonstrates BMS’ commitment to expanding their presence in Europe and strengthening their global supply network.
